1. bookVolume 64 (2014): Issue 2 (June 2014)
Journal Details
License
Format
Journal
eISSN
1820-7448
First Published
25 Mar 2014
Publication timeframe
4 times per year
Languages
English
access type Open Access

Delayed Behavioral Effects of SH–I–048A, a Novel Nonselective Positive Modulator of Gabaa Receptors, After Peripheral Nerve Injury in Rats

Published Online: 17 Jun 2014
Volume & Issue: Volume 64 (2014) - Issue 2 (June 2014)
Page range: 189 - 199
Received: 31 Dec 2013
Accepted: 13 Mar 2014
Journal Details
License
Format
Journal
eISSN
1820-7448
First Published
25 Mar 2014
Publication timeframe
4 times per year
Languages
English
Abstract

The complex clinical picture of mono-neuropathy following injury of peripheral nerve is often accompanied by changes in the patients’ affective states. It has been shown that positive allosteric modulators of GABAA receptors can decrease nociceptive transmission in animal pain models. However, recent findings suggest a possibility that at least some of the antinociceptive effects of benzodiazepines, related to neuropathic painful stimuli, may to a significant degree be a consequence of their anxiolytic action.

In this study we evaluated the possible delayed effects of SH-I-048A, a newly- synthesized high-efficacy nonselective positive modulator of GABAA receptors, on anxiety-like behavior and locomotor activity in Wistar rats with a previously induced peripheral nerve injury.

Assessment of behavioral parameters, using spontaneous locomotor activity and elevated plus maze tests, was performed 48h after completion of single-day threei. p. injections treatment consisting of zero, one, two or three doses of SH-I-048А (10 mg/kg).

In general, rats’ behavior observed 72 h after a moderate peripheral nerve injury did not indicate the persistence of sequelae of mono-neuropathic pain. The rats treated with three doses of SH-I-048А displayed an enhanced immobility time in the locomotor activity test, without concomitant decrease of the total distance traveled. On the other hand, in the group treated with two doses of SH- I-048А, a decrease in the emotional reactivity in the elevated plus maze test was observed. Subtle changes in the regimen of dosing of SH-I-048А affect locomotor activity and anxiety-related behavior in animals with peripheral nerve injury.

Keywords

1. Gormsen L, Rosenberg R, Bach FW, Jensen TS: Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain 2010, 14:127.e1-8.10.1016/j.ejpain.2009.03.01019473857Search in Google Scholar

2. Munro G, Ahring PK, Mirza NR: Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009, 30:453-9.10.1016/j.tips.2009.06.00419729210Search in Google Scholar

3. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU: Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 2009, 141:233-8.10.1016/j.pain.2008.10.01519091469Search in Google Scholar

4. Malan TP, Mata HP, Porreca F: Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology 2002, 96:1161-7.10.1097/00000542-200205000-0002011981157Search in Google Scholar

5. Casarrubea M, Sorbera F, Santangelo A, Crescimanno G: The effects of diazepam on the behavioral structure of the rat’s response to pain in the hot-plate test: anxiolysis vs. pain modulation. Neuropharmacology 2012, 63:310-21.10.1016/j.neuropharm.2012.03.02622521500Search in Google Scholar

6. Stahl SM: Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 2002, 63:756-7.10.4088/JCP.v63n090112363113Search in Google Scholar

7. Sieghart W, Ernst M: Heterogeneity of GABAA receptors: revived interest in the development of subtype-selective drugs. Curr Med Chem - Central Nervous System Agents 2005, 5:217-242.10.2174/1568015054863837Search in Google Scholar

8. Auta J, Kadriu B, Giusti P, Costa E, Guidotti A. Anticonvulsant, anxiolytic, and non- sedating actions of imidazenil and other imidazo-benzodiazepine carboxamide derivatives. Pharmacol Biochem Behav 2010, 95:383-9.10.1016/j.pbb.2010.02.01620227434Search in Google Scholar

9. Rabe H, Kronbach C, Rundfeldt C, Lüddens H: The novel anxiolytic ELB139 displays selectivity to recombinant GABA(A) receptors different from diazepam. Neuropharmacology 2007, 52:796-801.10.1016/j.neuropharm.2006.09.01317087982Search in Google Scholar

10. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Möhler H: Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999, 401:796-800.10.1038/4457910548105Search in Google Scholar

11. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000, 3:587-92.10.1038/7576110816315Search in Google Scholar

12. Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, et al: Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008, 451:330-4.13.10.1038/nature0649318202657Search in Google Scholar

13. Cook JM, Huang S, Sarma PVVS, Zhang C, Zhou H; Wisys Technology Found Inc, James M Cook, Hao Zhou, Shengming Huang, P V V S Sarma, Chunchun Zhang, assignee. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedativehypnotic and ataxic effects. United States patent US WO2006004945 A1 2006 Jan 12. [http://patentscope.wipo.int/search/en/WO2006004945]Search in Google Scholar

14. Drexler B, Zinser S, Huang S, Poe MM, Rudolph U, Cook JM, Antkowiak B: Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states. Eur J Pharmacology 2013, 5:703.10.1016/j.ejphar.2013.01.034399667623380687Search in Google Scholar

15. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA: A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 2011, 36:1903-11.10.1038/npp.2011.76315410921562483Search in Google Scholar

16. Bridge PM, Ball DJ, Mackinnon SE, Nakao Y, Brandt K, Hunter DA, et al: Nerve crush injuries--a model for axonotmesis. Exp Neurol 1994, 127:284-90.10.1006/exnr.1994.11048033968Search in Google Scholar

17. Savić MM, Huang S, Furtmüller R, Clayton T, Huck S, Obradović DI, et al: Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists? Neuropsychopharmacology 2008, 33:332-9.10.1038/sj.npp.130140317392731Search in Google Scholar

18. Savić MM, Majumder S, Huang S, Edwankar RV, Furtmüller R, Joksimović S, et al: Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats? Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:376-86.10.1016/j.pnpbp.2010.01.004285962420074611Search in Google Scholar

19. Savić MM, Obradović DI, Ugresić ND, Cook JM, Yin W, Bokonjić DR: Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol Biochem Behav 2004, 79:279-90.10.1016/j.pbb.2004.07.01315501303Search in Google Scholar

20. Dworkin RH: An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002, 18:343-9.10.1097/00002508-200211000-0000112441827Search in Google Scholar

21. Finnerup NB, Sindrup SH, Jensen TS: The evidence for pharmacological treatment of neuropathic pain. Pain 2010, 150:573-81.10.1016/j.pain.2010.06.01920705215Search in Google Scholar

22. O’Connor AB, Dworkin RH: Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009, 122:S22-32.10.1016/j.amjmed.2009.04.007Search in Google Scholar

23. Ellis A, Bennett DL: Neuroinflammation and the generation of neuropathic pain. Br J Anaesth 2013, 111:26-37.10.1093/bja/aet128Search in Google Scholar

24. Naik AK, Latham JR, Obradovic A, Jevtovic-Todorovic V: Dorsal root ganglion application of muscimol prevents hyperalgesia and stimulates myelin protein expression after sciatic nerve injury in rats. Anesth Analg 2012, 114:674-82.10.1213/ANE.0b013e31823fad7eSearch in Google Scholar

25. Huston JP, Schulz D, Topic B: Toward an animal model of extinction-induced despair: focus on aging and physiological indices. J Neural Transm 2009, 116:1029-36.10.1007/s00702-009-0210-4Search in Google Scholar

26. Ryan CG, Gray HG, Newton M, Granat MH: The relationship between psychological distress and free-living physical activity in individuals with chronic low back pain. Man Ther 2010, 15:185-9.10.1016/j.math.2009.10.007Search in Google Scholar

27. Divljaković J, Milić M, Timić T, Savić MM: Tolerance liability of diazepam is dependent on the dose used for protracted treatment. Pharmacol Rep 2012, 64:1116-25.10.1016/S1734-1140(12)70908-8Search in Google Scholar

28. Friedman H, Abernethy DR, Greenblatt DJ, Shader RI: The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. Psychopharmacology 1986, 88:267-70.10.1007/BF001808223083446Search in Google Scholar

29. Samardžić J, Puškaš L, Obradović M, Lazić-Puškaš D, Obradović D: Antidepressant effects of an inverse agonist selective for α5 GABA-A receptors in the rat forced swim test, Acta Vet (Beograd) 2014, 64(1):52-60. 10.2478/acve-2014-0006Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo